Background Venous resection may be required to achieve complete resection of pancreatic cancers. We assessed the ability of radiographic criteria to predict the need for superior mesenteric-portal vein (SMV-PV) resection and the presence of histologic vein invasion. Methods All patients who underwent pancreaticoduodenectomy from 2004 to 2011 at the authors' institution were identified. Preoperative pancreatic protocol CT images were re-reviewed to characterize the extent of tumor-vein circumferential interface (TVI) as demonstrating no interface, ≤180°of vessel circumference, >180°of vessel circumference, or occlusion. Findings were correlated with the need for venous resection, histologic venous invasion, and survival. Results A total of 254 patients underwent pancreaticoduodenectomy and met inclusion criteria; 98 (39.6 %) required SMV-PV resection. In our cohort, 76.4 % of patients received neoadjuvant chemoradiation. The TVI classification system predicted with fair accuracy both the need for SMV-PV resection at the time of surgery and histologic invasion of the vein. In particular, 89.5 % of patients with TVI >180°or occlusion required SMV-PV resection. Of those, 82.4 % had documented histologic SMV-PV invasion. TVI ≤180°was associated with favorable overall survival compared to a greater circumferential interface. Conclusions A tomographic classification of the tumor-SMV-PV interface can predict the need for venous resection, pathologic venous involvement, and survival. To assist in treatment planning, a standardized assessment of this anatomic relationship should be routinely performed.
Introduction
Tumor invasion of the superior mesenteric vein/portal vein (SMV-PV) by pancreatic ductal adenocarcinoma of the head of the pancreas (PDAC) is common due to the anatomic proximity of the venous confluence to the pancreatic head. Historically, such vascular involvement represented a contraindication to surgical resection because it was perceived that pancreaticoduodenectomy (PD) with concomitant vein resectionoften performed by an unprepared surgical team following intraoperative identification of venous involvement by cancer-was a high-risk operation associated with a low likelihood of yielding a complete resection of the tumor or long-term survival. 1 , 2 Over the past two decades, however, improvements in cross-sectional imaging have allowed for more detailed preoperative planning and have contributed to operative safety. In addition, improvements in neoadjuvant therapies have resulted in a larger group of patients being considered for extended surgical procedures involving the SMV-PV. Multiple recent series have demonstrated that venous resection and reconstruction during pancreaticoduodenectomy (PD) can now be performed safely and may result in favorable survival rates in properly selected patients.
3 -5 Many pancreatic treatment centers now routinely perform venous resection and reconstruction with PD, with or without neoadjuvant therapy.
Characterization of the anatomic relationship between the tumor and the vessels on radiographic images has thus become a critical step in the preoperative and intraoperative decision-making processes for patients with PDAC. Several radiographic classification systems have been developed to describe this relationship in an effort to alert the operative team of the potential need for vascular resection/ reconstruction.
6 -9 However, few studies have explored the association between radiographic indicators and either histopathologic findings or long-term oncologic outcomes. Furthermore, the radiographic classification systems that have been developed have assumed a surgery first treatment algorithm. Their applicability following treatment with preoperative therapy-increasingly used in the management of patients with both resectable and borderline resectable tumors that involve the mesenteric vasculature-is therefore unknown.
In this study, we sought to evaluate the ability of a simple set of tomographic criteria to predict the need for venous resection at the time of surgery, the presence of histologic invasion of the vein wall, and the overall survival of patients who had and had not received chemoradiation therapy prior to PD. To this end, we re-reviewed the preoperative cross-sectional imaging studies of 277 consecutive patients who underwent curative resection of pancreatic head adenocarcinoma and correlated the circumferential radiographic interface between the primary tumor and the SMV-PV with intraoperative events, histopathologic results, and long-term oncologic outcomes.
Patients and Methods
The institutional review board of the University of Texas M.D. Anderson Cancer Center approved this study. Clinical data on all patients who underwent PD for PDAC between 2004 and 2011 at MDACC were retrieved from the institutional pancreatic tumor database prospectively maintained by the Department of Surgical Oncology. 10 Patients who did not receive preoperative computed tomography (CT) imaging using pancreatic protocol within three months of surgery were excluded from analysis, as were patients whose final diagnosis was invasive PDAC arising from an intraductal papillary mucinous neoplasm or mucinous cystic neoplasm.
Radiographic Evaluation
Anatomic disease evaluation was accomplished with multidetector CT using a 16-detector or 64-detector row scanner (General Electric Medical Systems, Milwaukee, WI, USA) and a standard protocol optimized for imaging pancreatic tumors, which consisted of a multiphasic CT with precontrast, late arterial, and portal venous phases of enhancement. The precontrast study extended from the top of the liver to the bottom of the liver. The late arterial phase of enhancement was typically obtained between 25 and 40 s from the start of the injection and the portal venous phase at 60 to 70 s delay. These phases covered the dome of the liver to the iliac crest. Delayed imaging through the kidneys at 90 s was also performed. Iodinated contrast was injected intravenously at a rate of 4 to 5 cc/s via a power injector. The portal venous phase of enhancement was used for evaluation of the portal, portal venous confluence, and superior mesenteric veins.
The preoperative CT images of each eligible patient were rereviewed for this study by a gastrointestinal radiologist faculty (A.B..), who was blinded to each patient's clinical history. The circumferential interface between the primary tumor and the SMV-PV was measured on axial images and designated as none (no direct interface, with either normal pancreas or fat separating the primary tumor from the vessel), ≤180°of the vessel circumference, >180°of the vessel circumference, or vascular occlusion (i.e., an absence of contrast within the lumen of the vein in association with adjacent tumor) (Fig. 1) . Although we routinely apply these tumor-vessel interface descriptors to both arteries (superior mesenteric artery, common hepatic artery, celiac trunk) and veins (SMV-PV) for radiographic staging purposes, here we sought to evaluate the ability of a simple set of radiographic criteria to predict both the need for superior mesenteric vein-portal vein (SMV-PV) resection at pancreatectomy and the histologic presence of SMV-PV invasion, so we focused on the tumor-vein interface (TVI) only.
technique. Gemcitabine-based systemic chemotherapy was delivered prior to chemoradiation in selected cases.
Surgical and Histopathologic Techniques
PD was performed using a standard technique. 13 The decision to perform venous resection and reconstruction was made by the operating surgeon based on an intraoperative assessment of the relationship between the tumor and the vein. When the primary tumor was adherent to and not easily separable from the vein, SMV-PV resection was performed either tangentially or segmentally as previously described.
14 Reconstruction of tangential resection consisted of either primary vein closure or patch venoplasty; segmental resection required bypass graft reconstruction with autologous internal jugular vein or, rarely, bioprosthetic material. 15 Pathologic evaluation of the specimen was performed using a standardized system, and surgical margins were designated in accordance with criteria of the 7th edition of the American Joint Committee on Cancer Staging Manual. 16 The final margin status of PD specimens was recorded as R0 (all margins negative microscopically), R1 (all margins grossly negative, but tumor cells present at any of the resected margins microscopically), or R2 (tumor identified grossly and microscopically at any of the margins). The closest distance between the cancer cells and the superior mesenteric artery margin was measured microscopically and prospectively recorded. 13 When applicable, the resected portion or segment of the SMV-PV was entirely submitted for histologic assessment. The inked vein margins were evaluated either perpendicularly for tangential SMV-PV resections or en face for segmental SMV-PV resections. Vein involvement by tumor was divided microscopically into four groups: (1) no tumor involvement, (2) tumor invasion into the tunica adventitia, (3) tumor invasion into the tunica media or intima, and (4) tumor invasion into the lumen of the SMV-PV with or without associated thrombus (Fig. 2) as previously described. 15 For clinicopathologic correlations, all patients who had SMV-PV resection but no histologic tumor involvement of the resected vessel and those who did not undergo SMV-PV resection at the time of PD (because the tumor was easily separable from the vein) were considered to have no vein involvement. Patients with proven histologic tumor invasion into any layer of the vein wall or its lumen were considered to have vein involvement by histology.
Follow-up and Statistical Analysis
Summary statistics were used to describe the study population. T-test (or one way ANOVA) and Pearson chi-square test (or Fisher's exact test) were used to assess differences in clinical/demographic characteristics by TVI categories, by venous resection, and by final pathologic results. Receiver operating characteristics (ROC) curves were constructed, and the areas under the curve (AUC) were calculated to evaluate the ability of TVI classification to predict the intraoperative need for vein resection and the presence of vein invasion. Overall survival (OS) was defined as the time from diagnosis to death or to the date of last follow-up if death did not occur. Progression-free survival (PFS) was calculated as the time from diagnosis to recurrence or death. The Kaplan-Meier product limit method was used to estimate the median survival durations for each clinical/demographic factor. Univariate Cox proportional hazard regression was used to identify any association between each of the variables and survival duration. Similar analyses were performed for PFS. Factors with a pvalue≤0.10 were included in the multivariate analyses. Statistical analysis was performed using Stata/SE version 12.1 statistical software (Stata Corp. LP, College Station, TX, USA).
Results

Clinicopathologic Patient Profile
A total of 277 patients with PDAC of the pancreatic head meeting inclusion criteria for this retrospective review underwent pancreaticoduodenectomy at MDACC from 2004 to 2011. The standardized institutional preoperative imaging study was not performed prior to surgery in 11 patients who were therefore excluded from the study, as were 12 additional patients whose final pathology demonstrated PDAC arising from a mucinous precursor lesion. The clinicopathologic characteristics of the remaining 254 patients are reported in Table 1 . Radiologic re-review of preoperative imaging studies classified the TVI of these patients as no interface (n =62, 24.4 %), ≤ 180°(n =154, 60.6 %), >180°(n =28, 11.0 %), and occlusion (n =10, 3.9 %).
Chemoradiation with or without induction chemotherapy was administered to 194 (76.4 %) patients prior to resection. At surgery, SMV-PV resection and reconstruction was performed in 98 (38.6 %) of 254 patients (58 via segmental resection and 40 via tangential resection), of whom 10 underwent concomitant resection of the common hepatic artery and/or its primary branches. Of the 98 patients who underwent SMV-PV resection and reconstruction, the initial histopathologic examination of the resected vein of 5 patients was incomplete and insufficient material existed for re-review. Among the remaining 93 patients with a complete histopathologic assessment of the vein, the wall of the resected vein was invaded by cancer in 64 (68.8 %): 17 tumors involved the tunica adventitia, 42 involved the tunica media/intima, and 5 invaded into the vein lumen.
TVI as a Predictor of Surgical and Pathologic Outcomes
Clinical characteristics and outcomes for each TVI category are reported in Table 2 . Primary cancers with a greater circumferential TVI were larger, more likely to have been treated with neoadjuvant CRT and more likely to have required SMV-PV resection at pancreatectomy (p <0.001). SMV-PV resection was performed in 8 (12.9 %) of the 62 patients with no TVI, 56 (36.4 %) of the 154 patients with a TVI≤180°, 25 (89.3 %) of the 28 patients with a TVI>180°, and 9 (90.0 %) of the 10 patients with venous occlusion (p <0.001). The rate of microscopically negative margins (R0 resection) among patients treated surgically was similar across TVI groups (p =0.25).
Receiver operating characteristic (ROC) curves were constructed to evaluate the ability of preoperative TVI to predict the need for SMV-PV resection and reconstruction (Fig. 3a) . A TVI threshold of any interface was associated with a high sensitivity (91.8 %) and a negative predictive value (87.1 %) for SMV-PV resection, but low specificity (34.6 %). Increasing the TVI threshold to 180°was associated with high specificity (97.4 %) and positive predictive value (89.5 %) for SMV-PV resection, but a low sensitivity (34.7 %). The area under the ROC curve (AUC) was 0.734 (Fig. 3a) .
Histopathologic vein involvement was identified in 2 (3.2 %) patients with no preoperative TVI (28.6 % of patients with no TVI who underwent SMV-PV resection), 34 (22. Subgroup analyses of patients resected with and without prior administration of chemoradiation therapy are reported in Table 2 . Resection and reconstruction of the SMV-PV at the time of pancreatectomy was associated with shorter median PFS (16.1 vs. 19.6 months, p =0.013) and OS (27.8 vs. 44.5 months, p =0.002) than pancreatectomy alone. Similarly, patients with vein involvement confirmed by histology had a shorter median PFS (15.6 vs. 19.6 months, p =0.001) and OS (27.0 vs. 40.4 months, p =0.001) than patients without tumor involvement of the vein. For survival analyses, patients were grouped into two main TVI groups: those with either no interface or a TVI measuring ≤180°and those with a TVI measuring >180°. This decision was based on the fact that the survival curve of patients with no interface was similar to that of patients with a TVI measuring ≤180°and that the survival curve of patients with a TVI measuring >180°was similar to that of patients with venous occlusion. Patients with TVI>180°had a shorter median PFS (15.9 vs. 18.2 months, p =0.006) and OS (30.9 vs. 37.3 months, p =0.030) than patients with an interface≤180° (Fig. 4) .
Discussion
Here, we evaluated objective radiographic, clinical, and pathologic parameters to determine the ability of the circumferential interface between the primary tumor and the SMV-PV on preoperative CT images to predict the need for venous resection at PD, histopathologic invasion of the vein wall in the surgical specimen, and overall survival of patients with PDAC. Among 254 patients who underwent surgical resection as either primary therapy or following neoadjuvant chemoradiation, both vein resection at PD and histopathologic involvement of the vein were more common among patients with a greater TVI on preoperative images. Although microscopically negative margins were achieved in over 90 % of patients regardless of the extent of preoperative TVI, an interface>180°was associated with shorter PFS and OS following resection. TVI thus represents a relevant clinical parameter that should be routinely measured and documented in standardized radiographic reports.
It has been well established that cross-sectional imaging studies of the pancreas provide information useful for perioperative planning. Prior studies have characterized the local anatomy on the basis of the radiographic relationship between the tumor and the vessel 6 , 7 , 9 , 14 or the radiographic appearance of the vessel itself 8 and have used classification schemes ranging from the simple 7 , 14 to relatively complex 6 , 8 , 9 on the basis of either cross-sectional CT images 6 , 7 , 9 , 14 or mesenteric angiograms. 8 Here, we have categorized TVI using a simple, objective scheme that characterizes the radiographic interface between the primary tumor and the SMV-PV as observed on routine cross-sectional CT images. Importantly, in describing this relationship, we have refrained from using subjective radiographic terms that have historically contributed to confusion with regard to local disease staging. For example, current NCCN guidelines distinguish resectable from borderline resectable cancers on the basis of "venous involvement of the SMV-PV demonstrating tumor abutment with impingement and narrowing of the lumen, encasement of the SMV-PV but without encasement of the nearby arteries, or shortsegment venous occlusion". 17 This terminology used in these guidelines leaves significant ambiguity as to which tumors should be considered resectable and which should be considered borderline resectable. To the extent that stage-specific treatment algorithms are dependent upon such designations, 18 the objective schema reported here may be used to individualize and optimize the treatments administered to patients with localized PDAC. Because resection of the adjacent mesenteric vasculature was historically viewed as the primary local contraindication to pancreatectomy, early studies primarily assessed the ability of radiographic observations to predict intraoperative inseparability of the tumor from the adjacent vessels. 7 , 9 , 14 As vascular resection has become increasingly accepted, additional work has examined the relationships between radiographic and histopathologic findings and prognosis following vein resection. We likewise found that PDAC of the pancreatic head that extends to the left of the SMV-PV has a more aggressive biologic phenotype than tumors that do not, regardless of the use of vein resection; in our series, patients with a TVI>180°h ad a shorter median PFS and OS than patients with no interface or a more limited interface. Importantly, however, the R0 resection rate was higher in our series-over 90 % in each TVI group-and did not differ based on the circumferential extent of TVI. The difference between our results and those from Nakao et al. may be due to our bias toward the administration of neoadjuvant chemoradiation (often in addition to systemic therapy) to all patients with borderline resectable PDAC, a practice not employed by Nakao even for more locally invasive cancers. Whether the high rate of marginnegative resection reported here despite extensive venous involvement is a reflection of the purported "sterilizing" effects of radiotherapy on surgical margins or selection bias, which is an important effect of neoadjuvant treatment sequencing, is unclear. Nevertheless, to the extent that most patients with PDAC die with local disease 21 and that future improvements in systemic therapies are likely to further emphasize the role for local cancer control, our findings suggest that chemoradiation may be a particularly important component of therapy for patients with radiographic evidence for significant venous involvement.
As a predictive tool, TVI criteria achieved fair accuracy in predicting the need for venous resection and histopathologic vein invasion. The absence of TVI on preoperative imaging was still associated with SMV-PV resection in 8 of 62 cases, but the vein was histologically involved by tumor in only 2 of them. On the other hand, a TVI>180°or venous occlusion was highly associated both with the need for venous resection and with histologic vein invasion. As expected, the least predictable TVI category was when the tumor shared an interface with up to half the circumference of the SMV-PV. In patients with such findings, vein resection was performed in over 1/3 of the patients, with 65 % of resected veins having histologic evidence of vein invasion. It is important to note that equivocal radiographic categories for determining vascular involvement or tumor resectability are not a function of this specific set of CT criteria, but instead represent a category of tumor-vessel relationship that exists across classification systems and commonly features some degree of unilateral vessel involvement, such as grade 2 of the Raptopoulos system (flattening or slight irregularity on one side of the vessel), 6 grade 2 of the Lu criteria (tumor is contiguous with 25-50 % of the vessel circumference), 7 , 22 or types II and III of the Ishikawa system (tumor causes a smooth shift and unilateral narrowing, respectively, of the PV).
8 , 23 Together, these findings suggest that (1) veins that bear no direct interface with the tumor are highly unlikely to require resection, and even less so to harbor malignancy if resected, (2) conversely, SMV-PVs with more than 180°of tumor interface or occlusion by the tumor are highly likely to need resection and to harbor malignancy, and (3) SMV-PVs that share an interface≤ 180°with the tumor may need to be resected and may harbor malignancy. This last point underscores the fact that, although preoperative imaging can be a useful adjunct in anticipating the need for SMV-PV resection, ultimately this decision rests with the operating surgeon at the time of surgery, who may deem this step necessary to safely resect the tumor and/or achieve clear surgical margins. Continued attempts at separating the pancreatic tumor from the SMV-PV that result in either an inadvertent venotomy or a grossly positive margin of resection must be avoided. A carefully planned venous resection/reconstruction is a much safer and oncologically superior operation.
Despite the significant number of patients in this series who had relatively advanced disease, the median OS for our entire study population, 33.1 months, compares favorably to published survival statistics for patients with resected PDAC. 5 , 24 , 25 Multiple studies have shown that SMV-PV resection and reconstruction can be performed safely as part of PD in well-selected patients, but conflicting data exist with regard to the association between vein resection and OS. who did not undergo vein resection concomitant with PD had a significantly longer OS (median 44.5 v. 27.8 months, p = 0.002) than that of patients who did. In our previous report of patients who underwent pancreaticoduodenectomy at our institution between 1990 and 2002, the median OS of patients who underwent venous resection (23.4 months) was similar to that of patients who did not (26.5 months, p =0.18). 3 The difference in these two studies, which largely reflects a relative improvement in survival among patients who did not require vascular resection (rather than a deterioration in survival among those who did), is likely due to improved patient selection (for example, the detection of small liver metastases on CT which were not visible in the past), increased experience of the multidisciplinary treatment team and all hospital providers, and more effective systemic therapies.
It is important to emphasize that we included only patients who underwent pancreatectomy in this study and reviewed only the preoperative CT scan. We did not examine changes in TVI that may have occurred in response to neoadjuvant therapy. In a recent analysis of patients with borderline resectable PDAC, many of whom are also reported in the present study, we demonstrated that significant radiographic "downstaging" was observed in the CT scans of only 1 of 129 patients. 27 The current report also excluded patients whose pancreatectomy was aborted based on intraoperative findings. At our institution, however, this is a rare event; among 92 patients in the previously cited study who were brought to the operating room for planned pancreatectomy, only 3 patients did not undergo resection due to unsuspected locally advanced disease. 27 These potential limitations notwithstanding, this study is notable for several fundamental strengths. First, our findings reflect the broad experience of a quaternary center for pancreatic disease that evaluates a significant number of "borderline resectable" cancers. Indeed, 76 % of the patients reported in this study, all of whom underwent pancreatectomy, had a direct radiographic interface between the tumor and the SMV-PV prior to surgery, and in 20 % of such patients, this interface measured >180°or was associated with complete venous occlusion. Our center therefore performs vascular resection in nearly 40 % of all pancreatic cancer operations. All patients were evaluated using a standardized, high-quality imaging protocol optimized for pancreatic imaging. We used standardized indications for surgery, standard operative techniques, and uniform methods of histopathologic analysis of the surgical specimen to include histologic review of the resected SMV-PV. Finally, all imaging studies were rereviewed for this analysis by a single gastrointestinal radiologist faculty to achieve uniform interpretation of the preoperative CT images in our study population.
Conclusion
In summary, a simple radiographic classification system that categorizes the circumferential interface between the tumor and the SMV-PV on preoperative imaging can be used to predict the need for SMV-PV resection at the time of pancreatectomy, histopathologic invasion of the resected vein, and overall prognosis of patients with resectable and borderline Next, tell us about the timing of CT imaging after neoadjuvant therapy. When do you repeat the CT scan after therapy and how close are these studies to your planned exploration.
Third, in the discussion you mentioned, but did not provide data, that the most frequent site of first recurrence of disease was distant metastases. Can you give us any information about the overall incidence of local recurrence, either as the first recurrence or late in the course?
Finally, all of your neoadjuvant therapy was Gemcitabine-based. We and many others have started using more aggressive neoadjuvant regimens for locally advanced disease, primarily with FOLFIRINOX. Our initial impression has been favorable, in terms of the response. In many cases, despite concerning CT imaging for both venous and arterial involvement, we have been able to complete R0 resections, usually without vascular resection. This has led us to be even more aggressive in these selected patients. Do you have any experience with FOLFIRINOX or similar regimens at MD Anderson and have you observed similar radiographic findings as you have in your Gemcitabine-based regimen?
Thanks again for an outstanding presentation.
Closing Discussant
Dr. Hop Tran Cao: Thank you Dr. Lillemoe for your excellent questions and insightful feedback. With regards to the issue of unresectability at the time of surgical exploration, this current series did not address that, as it only included patients who received pancreaticoduodenectomy. However, we have previously reviewed our experience with patients receiving neoadjuvant chemoradiation, and found that high-quality pancreatic protocol CT scans were highly accurate in predicting surgical resectability at the time of surgery. Local factors caused us to abort surgical resection at the time of exploration in only 3 % of cases, too small a number for us to really be able to correlate TVI classes with resectability. As long as the CT scan demonstrates criteria of borderline resectability and not locally advanced disease, the primary tumor should be technically resectable in our experience.
As for the timing of the preoperative CT scan, these are routinely obtained within a week of surgery at our institution.
In looking back at our data, the overall incidence of initial local recurrence (alone or concurrent with distant disease) in our cohort was approximately 25 % among all patients who recurred, and 17 % among all patients who underwent PD and who were reported in this study.
Finally, we are also gaining experience with FOLFIRINOX in the neoadjuvant setting. However, our experience with this regimen is much too young to draw any conclusions with regards to imaging criteria or vascular resection at this time.
